Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fumoleau

Showing results (31-40 of 110) with videos related to

Pageof 11
Sort By:
Annales De Biologie Clinique|July 29, 2017
Clinical value of CA 15-3 for detection of distant metastases in newly diagnosed breast cancerBarbara Gonssaud, Vincent Goussot, Alina Berriolo-Riedinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignanciesVéronique Diéras, Jacques Bonneterre, Valérie Laurence, et al.
Breast (Edinburgh, Scotland)|August 19, 2007
Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancerLaure Favier, Nicolas Isambert, Sylvie Zanetta, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2005
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC studyAlain Ravaud, Thomas Cerny, Catherine Terret, et al.
Cancer|October 21, 2006
Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 TrialCorinne Veyret, Christelle Levy, Philippe Chollet, et al.
Annales De Pathologie|February 5, 2017
[The anti-tumor immune response in breast cancer: Update and therapeutic perspectives]Sylvain Ladoire, Valentin Derangère, Laurent Arnould, et al.
Breast (Edinburgh, Scotland)|August 7, 2012
Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year studySéverine Guiu, Laurent Arnould, Franck Bonnetain, et al.
British Journal of Clinical Pharmacology|November 29, 2013
How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I studyNicolas Isambert, Jean Pierre Delord, Jean Marc Tourani, et al.
Investigational New Drugs|October 28, 2003
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancerChristian Dittrich, Veronique Dieras, Pierre Kerbrat, et al.
European Journal of Cancer (Oxford, England : 1990)|December 10, 2013
Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trialsSylvain Ladoire, Cecile Dalban, Henri Roché, et al.
Pageof 11

Showing results (31-40 of 110) with videos related to

Sort By:
Pageof 11
Annales De Biologie Clinique|July 29, 2017
Clinical value of CA 15-3 for detection of distant metastases in newly diagnosed breast cancerBarbara Gonssaud, Vincent Goussot, Alina Berriolo-Riedinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignanciesVéronique Diéras, Jacques Bonneterre, Valérie Laurence, et al.
Breast (Edinburgh, Scotland)|August 19, 2007
Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancerLaure Favier, Nicolas Isambert, Sylvie Zanetta, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2005
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC studyAlain Ravaud, Thomas Cerny, Catherine Terret, et al.
Cancer|October 21, 2006
Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 TrialCorinne Veyret, Christelle Levy, Philippe Chollet, et al.
Annales De Pathologie|February 5, 2017
[The anti-tumor immune response in breast cancer: Update and therapeutic perspectives]Sylvain Ladoire, Valentin Derangère, Laurent Arnould, et al.
Breast (Edinburgh, Scotland)|August 7, 2012
Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year studySéverine Guiu, Laurent Arnould, Franck Bonnetain, et al.
British Journal of Clinical Pharmacology|November 29, 2013
How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I studyNicolas Isambert, Jean Pierre Delord, Jean Marc Tourani, et al.
Investigational New Drugs|October 28, 2003
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancerChristian Dittrich, Veronique Dieras, Pierre Kerbrat, et al.
European Journal of Cancer (Oxford, England : 1990)|December 10, 2013
Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trialsSylvain Ladoire, Cecile Dalban, Henri Roché, et al.
Pageof 11